Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Weight Loss Drugs Obesity Treatments FDA Approval Regulatory Approval Bexobrutideg RNA-based Therapies Hair Loss Treatments Polilaminina Psilocybin Therapy Prostate Cancer Therapeutics B-cell Malignancies Obesity Drugs AZD5904 Tourette Syndrome Eli Lilly and Company Gilead Sciences Atezolizumab Foundayo Prostate Cancer Therapies Acasunlimab Immunoglobulin A Nephropathy CagriSema Market Competition Experimental Drugs Regulatory Submissions Alzheimer's Disease Combination Therapy Bayer Phase Three Trials CS2009 Hemophilia Treatments Psychoactive Drugs Schizophrenia Phase III Trials Biomarkers Collaboration Agreements Regulatory Approvals Weight Loss Treatments Market Potential Moderna Asundexian Preclinical Research Efficacy Studies Novo Nordisk Liver Therapies Tonix Pharmaceuticals Market Impact Phase I Trial AI in Drug Discovery Anti-inflammatory Drugs Schizophrenia Treatments Cancer Treatments Outlicensing Market Analysis Phase II Trial Market Approval Obexelimab Zaltenibart Weight Loss Medications Synthetic Psilocybin Eli Lilly Phase 3 Trials

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

The deal gives AstraZeneca the commercial scale to broaden access to the EGFR exon 20 insertion drug while first-line approval reviews continue.

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion